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Introduction 
 
Xanthohumol (XN) is the principal prenylated 
chalcone of the female inflorescences (hop 
cones, hops) of the hop plant Humulus lupulus 
L. and it has been shown to have several benefi-
cial biological activities. Among them its chemo-
preventive and anti-inflammatory properties are 
the most extensively investigated [1, 2], and 
these are at least in part mediated via inhibition 
of the NFκB signaling pathway [3-6]. We have 
shown previously that XN inhibits hepatic in-
flammation and fibrosis in a murine model of 
non-alcoholic fatty liver disease (NAFLD) [6]. 
NAFLD is considered as the most frequent liver 
disease in Western countries [7-9]. It is charac-
terized by hepatocellular lipid accumulation, on 
the ground of which inflammation and fibrosis 
may develop. The histological picture closely 
resembles alcoholic liver disease [10]. In non-
alcoholic steatohepatitis (NASH) and alcoholic 
steatohepatitis (ASH) as well as in other chronic 
liver diseases like viral hepatitis, hepatic fibrosis 
is the peril that determines morbidity and mor-
tality. Cirrhosis, as the end stage of hepatic fi-
brosis, is a major clinical issue for its high 
prevalence in the world and its tight relationship 
with hepatocellular carcinoma incidence [11-
13]. Hepatic fibrosis is characterized by an ex-
cessive and aberrant deposition of extracellular 
matrix (ECM) proteins in the liver, the most 
abundant of which is collagen type I [14]. Acti-
vated hepatic stellate cells (HSC) are the cellu-
lar source of the excessive ECM deposition [15-
17]. Normally, these cells are quiescent and 
produce only small amounts of ECM compo-
nents, such as laminin and collagen type IV, 
during the formation of basement membrane 
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Abstract: Xanthohumol, the major prenylated chalcone found in hops, is known for its anti-inflammatory properties. 
We have recently shown that xanthohumol inhibits hepatic inflammation and fibrosis in a murine model of non-
alcoholic steatohepatitis. The aim of this study was to investigate the effect of xanthohumol in an acute model of liver 
injury. Carbon tetrachloride (CCl4), an industrial solvent, is a hepatotoxic agent and its administration is widely used 
as an animal model of toxin-induced liver injury. Xanthohumol was applied orally at a dose of 1 mg/g body weight 2 
days prior as well as during and after exposure to CCl4. 72 h after a single CCl4 application histomorphology and se-
rum levels of transaminases revealed considerable hepatocellular necrosis, which was accompanied by significantly 
enhanced hepatic expression of pro-inflammatory cytokines. Furthermore, elevated hepatic alpha-smooth muscle 
actin expression indicated activation of hepatic stellate cells, and in accordance, we detected enhanced hepatic ex-
pression levels of TGF-β and collagen type I reflecting a marked fibrogenic response to CCl4 exposure. While the de-
gree of hepatocellular damage in response to CCl4 was similar in mice which received xanthohumol and the control 
group, pro-inflammatory and profibrogenic hepatic gene expression were almost completely blunted in xanthohumol 
fed mice. Furthermore, xanthohumol fed mice revealed decreased hepatic NFκB activity. These results suggest that 
the protective effects of xanthohumol in this toxic liver injury model involves direct mechanisms related to its ability to 
block both hepatic inflammation and the activation of hepatic stellate cells, presumable at least in part via decreas-
ing NFκB activity. Thus, this study further indicates the potential of xanthohumol application to prevent or ameliorate 
the development and progression of liver fibrosis in response to hepatic injury. 
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[18]. However, in response to hepatic injury HSC 
get activated and transform into a myofibroblast
-like phenotype, expressing alpha-smooth mus-
cle actin (α-SMA), and dramatically increase the 
production of collagens [19]. Importantly, the 
transcription factor NFκB plays a crucial role in 
HSC activation [20, 21, 15, 22].  
 
In addition to metabolic overload, alcohol or 
viral infection the liver is frequently exposed to 
various insults, including toxic chemicals [23, 
24]. Liver damage caused by hepatotoxic 
chemicals induces compensatory hepatic hyper-
plasia after severe liver necrosis due to direct 
damage of hepatocytes and subsequent inflam-
mation [25]. Carbon tetrachloride (CCl4), an in-
dustrial solvent, is a hepatotoxic agent and its 
administration is widely used as an animal 
model of toxin-induced liver injury that allows 
the evaluation of both necrosis and subsequent 
inflammation [26] as well as fibrosis [27]. In 
contrast to our previously used NASH-model 
which led to only mild hepatocellular damage 
and inflammation [6], CCl4 application results in 
excessive necrotic and apoptotic death of hepa-
tocytes, which induces the activation of HSC.  
 
To investigate the effect of XN on acute liver 
injury and to further study its role in liver fibro-
sis, we subjected mice, which were treated with 
and without XN at a dose of approximately 1 
mg/g body weight, to acute CCl4-induced liver 
damage. 
 
Methods 
 
Chemicals and animal feeds 
 
Carbon tetrachloride (CCl4) and olive oil were 
obtained from Sigma Pharmaceuticals 
(Hamburg, Germany). Xanthohumol (XN) was 
obtained from Alexis Biochemicals (Lausen, 
Switzerland) with a purity  98% determined by 
HPLC. All chows were prepared by Ssniff (Soest, 
Germany).  
 
CCl4-induced acute liver injury 
 
A single dose of CCl4 (1 µl/g body weight in olive 
oil) was intraperitoneally injected to 10 weeks 
old female BALB/c mice. 72 h after CCl4 injec-
tion, mice were killed by heart puncture under 
deep ketamine/xylazine (2:1) anesthesia, and 
liver tissue and blood samples were collected 
for further analysis. Livers and blood from olive 
oil treated animals served as controls.  
Histology 
 
For histological analysis murine liver tissue 
specimens were fixed for 24 h in 4% formalin at 
room temperature, dehydrated by graded etha-
nol and embedded in paraffin. Tissue sections 
(thickness 5 µm) were deparaffinized with xy-
lene and stained with eosin/haematoxylin (H&E) 
as described [28]. 
 
Quantitative real time-PCR analysis 
 
RNA isolation from liver tissue and reverse tran-
scription were performed as described [29]. 
Quantitative real time-PCR was performed ap-
plying LightCycler technology (Roche, Mann-
heim, Germany) as described [30] applying the 
following pairs of primers: murine collagen-I (for: 
5'-CGG GCA GGA CTT GGG TA; rev: 5'-CGG AAT 
CTG AAT GGT CTG ACT) and murine MCP-1 (for: 
5'-TGG GCC TGC TGT TCA CA; rev: 5'-TCC GAT 
CCA GGT TTT TAA TGT A). All other mRNA expres-
sion analyses were performed using QuantiTect 
Primer Assays according to the manufacturer's 
instructions (Qiagen, Hilden, Germany). Amplifi-
cation of cDNA derived from 18s rRNA (for: 5'-
AAA CGG CTA CCA CAT CCA AG; rev: 5'-CCT CCA 
ATG GAT CCT CGT TA) was used for normaliza-
tion. 
 
Quantification of NFκB activity 
 
Liver tissue extracts were obtained by homog-
enization of snap-frozen liver tissue in Cell Lysis 
Buffer from Cell Signaling (Danvers, MA, USA) 
supplemented with 1 mM PMSF and a protease 
inhibitor cocktail (cOmplete Mini Protease In-
hibitor Cocktail Tablets from Roche Diagnostics, 
Mannheim, Germany) using a MICCRA D1 ho-
mogenizer (ART Prozess- & Labortechnik, Müll-
heim, Germany), and subsequent sonication 
(with a Sonopuls HD 70 from Bandelin electron-
ics, Berlin, Germany) and centrifugation. Acti-
vated NFκB was quantified in liver tissue ex-
tracts via ELISA-technique using the PathScan 
Phospho-NFκB p65 (Ser536) Sandwich ELISA 
Antibody Pair from Cell Signaling following the 
manufacturer's protocols as described [6]. 
 
Statistical analysis 
 
Values are presented as mean ± SEM. Compari-
son between groups was made using the Mann 
Whitney test. A p value <0.05 was considered 
statistically significant. All calculations were 
performed using the statistical computer pack-
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age GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego, Ca, USA). 
 
Results 
 
Effect of xanthohumol on hepatocellular dam-
age in toxin induced liver injury 
 
To assess the effect of xanthohumol (XN) in the 
model of carbon tetrachloride (CCl4) induced 
toxic liver injury mice were fed with control chow 
or a diet containing 0.5% (w/w) XN resulting in a 
daily dose of approximately 1 mg/g body weight 
(BW). After 2 days of XN-feeding, mice received 
a single dose of CCl4 (1 µl/g BW) or the same 
volume of the pure solvent (olive oil). Feeding of 
XN or control chow was continued, and 3 days 
after CCl4 application mice were sacrificed. At 
this time body weight did not differ significantly 
between control mice (18.2 ± 1.3 g) and XN-fed 
(18.3 ± 0.2 g) animals, and mice receiving CCl4 
alone (16.4 ± 1.3 g) or CCl4 together with XN 
(16.8 ± 0.4 g). However, liver weight and liver to 
body weight ratio, respectively, were signifi-
cantly elevated in CCl4-treated mice but did not 
differ between XN- and control chow-fed mice 
(Figure 1A). Macroscopically, livers of CCl4- 
treated mice were larger and revealed a pale 
and irregular surface indicative of severe hepa-
tocellular damage (Figure 1B). Histopathological 
analysis confirmed large areas of necrotic tissue 
in the central zones of the livers of CCl4-treated 
mice with no significant differences between 
the XN-fed and control chow-fed group (Figure 
1C). Hepatocellular damage in the CCl4 groups 
was also reflected by a marked increase of se-
rum transaminases compared to both control 
groups, which was similar in XN-fed and control 
chow-fed mice (Figure 1D and 1E). 
 
Effect of xanthohumol on hepatic inflammation 
and fibrosis in toxin induced liver injury 
 
To determine whether XN affects the inflamma-
tory response after acute CCl4-mediated liver 
injury we analyzed the expression of pro-
inflammatory cytokines in injured livers using 
semi-quantitative real-time PCR. 72 h after CCl4- 
injection, hepatic mRNA expression levels of 
tumor necrosis factor (TNF) and interleukin-1 
alpha (IL-1α) were significantly elevated in mice 
without XN-feeding. In contrast, inflammatory 
gene expression was almost completely blunted 
in CCl4-treated mice by XN-feeding (Figure 2A 
and 2B). Similar results were obtained when 
analyzing hepatic mRNA expression of mono-
cyte chemoattractant protein-1 (MCP-1) and 
intercellular adhesion molecule-1 (ICAM-1) 
(Figure 2C and 2D), both genes which are 
strongly regulated by the transcription factor 
NFκB. In line with these and previous in vitro 
findings by our group [6, 31] and others [3-6] 
we found 72 h after CCl4-injection significantly 
lower hepatic NFκB activity in XN-fed mice com-
pared to control chow-fed animals (Figure 2D).  
 
Next, we determined if the reduced inflamma-
tion seen in CCl4-treated and XN-fed mice is 
reflected by down-regulation of genes that medi-
ate the fibrotic response. Levels of TGF-β mRNA 
were markedly induced in control chow-fed CCl4-
treated mice while in XN-fed CCl4-treated mice 
expression levels of this cytokine, which plays a 
crucial pathophysiological role in liver fibrosis 
[32, 33], were not elevated compared to control 
mice (Figure 3A). In addition, expression of  
genes encoding collagen type I (Coll-I) and tis-
sue inhibitor of matrix metalloproteinase-1 
(TIMP-1) were induced after CCl4-treatment, but 
this increase was inhibited by XN application 
(Figure 3B and 3C). The expression of these 
genes reflects the onset of tissue remodeling 
processes, which can lead to fibrosis [34]. In 
line with this, a significant increase of alpha-
smooth muscle actin (α-SMA) expression was 
observable in control chow-fed but not in XN-fed 
mice after CCl4-treatment, indicating a XN-
mediated inhibition of injury-triggered HSC acti-
vation (Figure 3D). These data indicate that liv-
ers of XN-fed animals display a diminished pro-
inflammatory and pro-fibrotic response after 
CCl4-induced injury. 
 
Discussion 
 
The aim of this study was to investigate the ef-
fect of xanthohumol (XN) in an acute model of 
liver injury and to further study its role in liver 
fibrosis. For this purpose we subjected mice fed 
with and without XN (at a dose of approximately 
1 mg/g body weight) to acute CCl4-induced liver 
damage. Our results reveal a profound inhibitory 
effect of XN on pro-inflammatory and pro-
fibrogenic hepatic gene expression in this 
model. Noteworthy, these effects occurred de-
spite the fact that hepatocellular injury as re-
flected by serum levels of transaminases or 
histomorphological analysis was comparable 
between control mice and XN-fed mice 72 h 
after CCl4-injection. These findings suggest that 
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the suppressive effect of XN against the pro-
gress of acute CCl4-induced hepatic fibrosis in-
volves direct mechanisms related to its ability to 
block both hepatic inflammation and the activa-
tion of hepatic stellate cells (HSC). Actually, we 
have previously shown that XN exhibits direct 
anti-inflammatory effects on HSC and inhibits 
the activation of these cells, respectively, by 
inhibiting IκBα degradation and subsequent 
NFκB activation [6]. Notably, these anti-
fibrogenic effects have been observed at con-
centrations as low as 5 µM. Previous studies 
Figure 1. Effect of xanthohumol on hepatocellular damage in toxin induced liver injury. Mice were fed either with 
control chow (ctr.) or with the same chow supplemented with 0.5% (w/w) xanthohumol (XN). After 2 days of feeding a 
single dose of CCl4 (1 µl/g body weight in olive oil) or olive oil alone (oil) was injected intraperitoneally to mice from 
both the control chow-fed and XN-fed group. 72 h after CCl4 or olive oil injection mice were sacrificed. (A) Liver-to-body
-weight-ratio (*: p<0.05). (B) Representative macroscopic images of livers from the four treatment groups. (C) HE-
staining of liver tissue. Necrotic areas are marked out by dotted lines. Black bars represent 0.5 mm. (D) AST and (E) 
ALT serum levels (*: p<0.05). 
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could not detect (unmetabolized and unconju-
gated) XN in the systemic circulation upon oral 
application [35, 36]. However, the anatomical 
situation of the liver has to be considered. It can 
be expected that after oral intake the XN con-
centration in the portal vein is higher than in the 
systemic circulation. Further, HSC are located in 
the liver in the space of Disse (or perisinusoidal 
Figure 2. Effect of xanthohumol on hepatic inflammation in toxin induced liver injury. Mice were fed either with control 
chow (ctr) or with the same chow supplemented with 0.5% (w/w) xanthohumol (XN). After 2 days of feeding a single 
dose of CCl4 (1 µl/g body weight in olive oil) or olive oil alone (oil) was injected intraperitoneally to mice from both the 
control chow-fed and XN-fed group. 72 h after CCl4 or olive oil injection mice were sacrificed. Analysis of hepatic 
mRNA levels of (A) TNF, (B) IL-1α, (C) MCP-1 and (D) ICAM-1 by quantitative RT-PCR (*: p<0.05 compared to oil-ctr; #: 
p<0.05 compared to CCl4-ctr). (E) Comparison of NFκB activity in livers of control chow-fed and XN-fed mice 72 h after 
CCl4-injection via ELISA-based quantification of phospho-p65 (Ser536) (*: p<0.05). 
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space), i.e. between the sinusoid and the hepa-
tocytes. Herewith, HSC are directly exposed to 
XN concentration reaching the liver via the por-
tal vein irrespective of (subsequent) metabolism 
in hepatocytes. Thus, XN concentrations reach-
ing HSC in the space of Disse may be signifi-
cantly higher than the levels in whole liver tis-
sue.  
 
In our previous study we have shown that XN 
inhibits hepatic inflammation and fibrosis in 
mice in a NASH model [6]. In this model hepato-
cellular lipid accumulation led to a mild inflam-
mation and fibrogenic response after 3 weeks 
of feeding a NASH inducing diet. In contrast, the 
CCl4-model is used to induce extended hepato-
cellular death and inflammation, which in turn 
promotes fibrosis. The marked anti-fibrogenic 
effect of XN under these acute and harsh ex-
perimental conditions further advances the con-
cept that XN is a promising natural substance 
with the potential to inhibit the development 
and progression of hepatic fibrosis in patients 
with (chronic) liver disease. 
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